Xenon Pharmaceuticals XENE Unrealized gains (losses) on available-for-sale securities
Unrealized gains (losses) on available-for-sale securities at other companies
Other financials
Where this comes from
Reported directly by Xenon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax.
The official record: Xenon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Xenon Pharmaceuticals's unrealized gains (losses) on available-for-sale securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Xenon Pharmaceuticals's unrealized gains (losses) on available-for-sale securities?
- Xenon Pharmaceuticals (XENE) reported unrealized gains (losses) on available-for-sale securities of -$1.55M in Q1 2026.
- How has Xenon Pharmaceuticals's unrealized gains (losses) on available-for-sale securities changed year-over-year?
- Xenon Pharmaceuticals's unrealized gains (losses) on available-for-sale securities decreased by 299.2% year-over-year, from $776K to -$1.55M.
- What is the long-term trend for Xenon Pharmaceuticals's unrealized gains (losses) on available-for-sale securities?
- Over 3 years (2022 to 2025), Xenon Pharmaceuticals's unrealized gains (losses) on available-for-sale securities has grown at a 1.3% compound annual growth rate (CAGR), from -$2.01M to $2.09M.
- What does unrealized gains (losses) on available-for-sale securities mean?
- This metric captures the unrealized gains or losses on investment securities classified as available-for-sale, which are recorded directly in equity rather than net income. It reflects the unrealized impact of market valuation changes on the company's long-term investment holdings. This figure is essential for understanding the total economic value of the company's investment portfolio beyond standard operating results.